Skip to main content

Home/ Dr. Goodyear/ Group items tagged Lymphoma

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
Nathan Goodyear

The telomerase activator TA-65 elongates short telomeres and increases health span of a... - 0 views

www.ncbi.nlm.nih.gov/...PMC3627294

TA-65 telomere Telomerase telomerase activator aging natural wellness health

shared by Nathan Goodyear on 16 May 16 - No Cached
  • studies have demonstrated that the shortest telomeres are causal of reduced cell viability
  • a stable and enforced expression of telomerase leads to an improved health-span, accompanied by an extension of lifespan
  • TA-65 influences the percentage of cellular short telomeres through the activation of telomerase
  • ...17 more annotations...
  • TA-65 administration during 4 months significantly improved the capacity to uptake glucose after a glucose pulse
  • liver protective action of TA-65
  • A disadvantage of mTERT potentiation could be associated to its capacity to favor proliferation of cancerous cells in murine models
  • TA-65 treated mice presented a similar incidence of malignant cancers at time of death, with a tendency to show decreased sarcomas and slightly increased lymphomas
  • We demonstrate here that TA-65 leads to a significant rescue of short telomeres through telomerase activation
  • TA-65 treatment increases proliferation and mobilization potential of mouse keratinocytes in vitro, a situation mimicking telomerase overexpression
  • TAT2, a similar molecule, have beneficial effects in the activation of CD8+ T lymphocytes from HIV-infected patients where they observe an increase of the proliferative potential and enhancement of cytokine/chemokine production
  • TA-65 resulted in a similar rescue of short telomeres in leukocytes post-treatment as observed with humans, most likely through an activation of telomerase
  • we observe that TA-65 lead to 10 fold increase of telomerase RNA levels in the liver of treated mice comparing to the non-treated same-age cohorts
  • TA-65 regulates telomerase at the transcription level, probably through the regulation of the MAPK pathway
  • TA-65 dependent telomerase activation results in a better organ fitness as demonstrated by the improved scores at the glucose tolerance test and insulin levels at fasting
  • TA-65 supplemented mice also present modest enhancement of the subcutaneous and epidermal thickness, as well as higher bone density, representative of an overall fitness status improvemen
  • TA-65 treated mice present higher levels of RBC and hemoglobin comparing to the control cohorts
  • improved health-span of TA-65 treated mice is not accompanied by increased cancer incidence, which may be related to the fact that TERT levels are very modestly increased in all tissues tested except for the liver
  • systemic telomerase overexpression from the germline leads to protection from aging associated pathologies
  • similar situation could be mimicked expressing telomerase late in life in a telomerase deficient background
  • we observed a higher proliferation rate and a partial protection from cell death in some tissues of TA65 treated mice
  • Nathan Goodyear on 16 May 16
     
    TA-65 shown to increase telomerase activity, and thus telomere length of short telomeres, in mouse study.  
Nathan Goodyear

Caloric restriction modulates Mcl-1 expression and sensitizes lymphomas to BH3 mimetic ... - 0 views

bloodjournal.hematologylibrary.org/...blood-2013-01-478651

calorie restriction cancer

shared by Nathan Goodyear on 28 Aug 13 - No Cached
  • Nathan Goodyear on 28 Aug 13
     
    Calorie restriction aids fight against cancer on several fronts.  Granted this is a mouse study, but Cancer should be attacked through nutrition just as through surgery and chemo/radiation.
Nathan Goodyear

Gamma-linolenic acid induces apoptosis in B-chroni... [Leuk Lymphoma. 2001] - PubMed re... - 0 views

www.ncbi.nlm.nih.gov/...11426562

gamma linolenic acid GLA cancer dexamethasone

shared by Nathan Goodyear on 11 Feb 11 - No Cached
  • n the presence of GLA 5 microg/ml and dexamethasone the degree of apoptosis was 86%
  • These results demonstrate that GLA induces apoptosis in B-CLL B- and T-cells cells in vitro and that they are more susceptible to GLA-induced apoptosis than normal peripheral blood B- and T-cells.
  • Nathan Goodyear on 11 Feb 11
     
    GLA, omega-6 found in plant based oils,  kills 42% of leukemia cells; with dexamethasone, the kill rate increases to 86%
Nathan Goodyear

The use of serum deoxythymidine kinase as a prognostic marker, and in the monitoring of... - 0 views

www.ncbi.nlm.nih.gov/...PMC2011337

thymidine kinase 1 TK-1cancer

shared by Nathan Goodyear on 11 Feb 15 - No Cached
  • Nathan Goodyear on 11 Feb 15
     
    Thymidine kinase 1 useful as a prognostic biomarker and to monitor therapy efficacy. TK-1 levels were very low in those without cancer. Higher TK-1 levels pretreatment were associated with poor prognosis and poor survival. TK-1 "increases with progress of the disease, decreases during successful therapy, and finally increases during relapse.
Nathan Goodyear

Serum Free Light Chain in Waldenstrom Macroglobulinemia. | Blood Journal - 0 views

www.bloodjournal.org/...2420

Waldenstrom lymphoma Cancer

shared by Nathan Goodyear on 30 Oct 18 - No Cached
  • Nathan Goodyear on 30 Oct 18
     
    Study found that elevated kappa and lambda light chains (sFLC's), as well as cytopenias, elevated Beta-2 macroglobulinemia correlated with poor response.
Nathan Goodyear

The Role of Serum Immunoglobulin Free Light Chain in Response and Progression in Walden... - 0 views

clincancerres.aacrjournals.org/...3013.long

Waldenstrom lymphoma "waldenstrom's macroglobulinemia" Cancer

shared by Nathan Goodyear on 30 Oct 18 - No Cached
  • Nathan Goodyear on 30 Oct 18
     
    Free Light Chains are useful in monitoring treatment success in Waldenstrom's Macroglobulinemia. On average, a response was seen 1 month earlier with the sFLC's than in the IgM. Also, appx 50% of patients receive rituxin had an IgM flare early in treatment.
Nathan Goodyear

https://www.researchgate.net/publication/258148681_An_unusual_case_of_Waldenstrom's_mac... - 0 views

www.researchgate.net/...ith_nasopharyngeal_involvement

Waldenstrom lymphoma "waldenstrom's macroglobulinemia" Cancer

shared by Nathan Goodyear on 30 Oct 18 - No Cached
  • Nathan Goodyear on 30 Oct 18
     
    Interesting case study of initiate presentation of Waldenstrom's Macroglobulinemia.
Nathan Goodyear

Pathophysiology of Waldenström's macroglobulinemia - 0 views

www.ncbi.nlm.nih.gov/...PMC2833063

Waldenstrom lymphoma "waldenstrom's Macroglobulinemia" Cancer

shared by Nathan Goodyear on 30 Oct 18 - No Cached
  • Nathan Goodyear on 30 Oct 18
     
    Great review of waldenstrom's macroglobulinemia.
Nathan Goodyear

Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratificatio... - 0 views

www.ncbi.nlm.nih.gov/...PMC2931618

Waldenstrom lymphoma "waldenstrom's macroglobulinemia" Cancer

shared by Nathan Goodyear on 30 Oct 18 - No Cached
  • Nathan Goodyear on 30 Oct 18
     
    A must read on waldenstrom's macroglobulinemia.
Nathan Goodyear

Waldenstrom's Macroglobulinemia: A Review of Laboratory Findings and Clinical Aspects |... - 0 views

academic.oup.com/...2657846

Waldenstrom lymphoma "waldenstrom's macroglobulinemia" Cancer

shared by Nathan Goodyear on 30 Oct 18 - No Cached
  • Nathan Goodyear on 30 Oct 18
     
    Nice brief synopsis of Waldenstrom's Macroglobulinemia.
Nathan Goodyear

Waldenstroms Macroglobulinemia Patient Presenting with Rare 'lytic' Lesions and Hyperca... - 0 views

www.ncbi.nlm.nih.gov/...PMC4290253

Waldenstrom lymphoma "waldenstrom's Macroglobulinemia" cancer

shared by Nathan Goodyear on 26 Oct 18 - No Cached
  • Nathan Goodyear on 26 Oct 18
     
    Interesting case study of sclerotic bone lesion in Waldenstrom's Macroglobulinemia.
Nathan Goodyear

http://downloads.hindawi.com/journals/crionm/2013/890864.pdf - 0 views

downloads.hindawi.com/...890864.pdf

Cancer Waldenstrom lymphoma "waldenstrom's Macroglobulinemia"

shared by Nathan Goodyear on 26 Oct 18 - No Cached
  • Nathan Goodyear on 26 Oct 18
     
    Case study of patient with Waldenstrom's macroglobulinemia
Nathan Goodyear

Waldenstrom's macroglobulinemia presenting with lytic bone lesions: a rare presentation - 0 views

www.ncbi.nlm.nih.gov/...PMC3786287

Waldenstrom lymphoma bone cancer

shared by Nathan Goodyear on 24 Sep 18 - No Cached
  • Nathan Goodyear on 24 Sep 18
     
    Waldenstrom's macroglobulinemia with osteolytic bone lesions.
Nathan Goodyear

Waldenstrom's Macroglobulinemia Associated Bone Disease the UAMS Experience | Blood Jou... - 0 views

www.bloodjournal.org/...2999

Waldenstrom lymphoma bone cancer

shared by Nathan Goodyear on 24 Sep 18 - No Cached
  • Nathan Goodyear on 24 Sep 18
     
    waldenstrom's macroglobulinemia found to have 24% bone disease.
Nathan Goodyear

Lytic Bone Lesions as a Prominent Feature in Waldenstrom's Macroglobulinemia. - PubMed ... - 0 views

www.ncbi.nlm.nih.gov/...19078464

Waldenstrom lymphoma cancer bone

shared by Nathan Goodyear on 24 Sep 18 - No Cached
  • Nathan Goodyear on 24 Sep 18
     
    Waldentstrom's macroglobulinemia with lytic bone lesions.  Only abstract available here.  Treatment, other than chemo, is radiation to effected site.
Nathan Goodyear

Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstr... - 1 views

www.ncbi.nlm.nih.gov/...18452095

Waldenstrom lymphoma "waldenstrom's macroglobulinemia" Cancer

shared by Nathan Goodyear on 30 Oct 18 - No Cached
  • Nathan Goodyear on 30 Oct 18
     
    Serum Free light chains helpful in the determination of prognosis and therapeutic response in patients with Waldenstrom's Macroglobulinemia.
Nathan Goodyear

IL-2: The First Effective Immunotherapy for Human Cancer | The Journal of Immunology - 0 views

www.jimmunol.org/...5451

cancer IL-2 Treg immune system immunology

shared by Nathan Goodyear on 17 Apr 18 - No Cached
  • IL-2 is a 15.5-kDa cytokine secreted predominately by Ag-simulated CD4+ T cells, but it can also be produced by CD8+ cells, NK cells, and activated dendritic cells
  • IL-2 is the predominant factor responsible for the maintenance of CD4+ regulatory T cells
  • A generalized capillary leak syndrome was induced by IL-2 in vivo that resulted in interstitial pulmonary infiltrates and substantial weight gain in patients
  • ...4 more annotations...
  • The side effects were transient and returned to baseline following treatment
  • Tumors do not express IL-2 receptors and thus the antitumor activity was the result of IL-2 stimulation of immune cell
  • Patients with metastatic melanoma or metastatic renal cell cancer were uniquely responsive to high-dose IL-2 administration, and except for patients with advanced non-Hodgkin’s lymphomas (35) only rare responses were seen in patients with other tumor types
  • The underlying toxicity of IL-2 results from a capillary leak that leads to fluid extravasation into visceral organs that can compromise their function
  • Nathan Goodyear on 17 Apr 18
     
    Great review of the history of IL-2 in the treatment of cancer.  IL-2 stimulates the immune system to attack cancer.  Don't reinvent the wheel; use what is already present and available.
Nathan Goodyear

PET/CT Standardized Uptake Values (SUVs) in Clinical Practice and Assessing Response to... - 0 views

www.ncbi.nlm.nih.gov/...PMC3026294

cancer PET scan PET_CT CT PET_CT scan

shared by Nathan Goodyear on 20 Feb 18 - No Cached
  • use of PET in clinical research, clinical trials, and drug discovery
  • use of PET/CT in assessing response to therapy
  • In some cases, such as Hodgkins lymphoma, quantitative PET/CT imaging may not actually be needed, as success can be defined by the complete absence of tracer uptake in the PET image following a course of standardized therapy
  • ...9 more annotations...
  • The utilization of PET/CT to assess response to therapy is increasing in the US related, in part, to the creation and subsequent favorable results of the National Oncologic PET Registry (NOPR)
  • Changes in size as a result of therapy may take many months to develop and any opportunity to make early decisions about therapy success or failure is often unduly delayed or lost altogether
  • measures of changes in metabolic activity via FDG PET/CT can provide an alternate approach to assess response to therapy -- often very early in the course of treatment
  • Current recommendations are that tumor SUVs should be reported
  • The true tracer uptake in a patient is composed of two components: the first being the amount of tracer uptake (e.g. FDG) associated with the disease status (the signal of interest), which can be modified by the biophysiological status of the patient. One of the more important patient parameters is the blood glucose level, which has been shown to inversely-linearly affect SUVs
  • A prospective study by Crippa et al.30 in eight patients showed that as blood glucose levels were increased from 92.4 ±10.2 to 158 ± 13.8 mg/100 ml by glucose loading, the average SUV of 20 liver metastases decreased from 9.4 ± 5.7 to 4.3 ± 8.3
  • chemotherapy can result in impaired renal function, significantly reducing the clearance of plasma FDG through the kidney and thus increasing tumor SUV relative to an initial PET scan
  • The second component of the true tracer uptake is biological variability
  • The biological variability has been estimated in several test-retest studies7,32–35 at approximately 10% for scans repeated within a few days
  • Nathan Goodyear on 20 Feb 18
     
    Good review of the SUVs of a PET/CT scan.
« First ‹ Previous 41 - 60 of 67 Next ›
Showing 20▼ items per page